Seminars in Oncology
Volume 33, Issue 6 , Pages 681-687 , December 2006

Selecting Endocrine Therapy for Breast Cancer: What Role Does HER-2/neu Status Play?

  • Tatiana M. Prowell

      Affiliations

    • Breast Cancer Research Program, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD.
    • ,
  • Deborah K. Armstrong

      Affiliations

    • Department of Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, Baltimore, MD.
    • Corresponding Author InformationAddress correspondence to Deborah K. Armstrong, MD, Associate Professor, Medical Oncology, Sidney Kimmel Comprehensive Cancer Center, Johns Hopkins, CRB-I, Room 190, 1650 Orleans St, Baltimore, MD 21231.

References 

  1. Pujol P, Daures JP, Thezenas S, et al. Changing estrogen and progesterone receptor patterns in breast carcinoma during the menstrual cycle and menopause. Cancer. 1998;83:698–705
  2. Osborne CK, Yochmowitz MG, Knight WA, et al. The value of estrogen and progesterone receptors in the treatment of breast cancer. Cancer. 1980;46:2884–2888
  3. Clark G, Osborne C, McGuire W. Correlations between estrogen receptor, progesterone receptor, and patient characteristics in human breast cancer. J Clin Oncol. 1984;2:1102–1109
  4. Earp HS, Dawson TL, Li X, et al. Heterodimerization and functional interaction between EGF receptor family members: A new signaling paradigm with implications for breast cancer research. Breast Cancer Res Treat. 1995;35:115–132
  5. Slamon DJ, Clark GM, Wong SG, et al. Human breast cancer: Correlation of relapse and survival with amplification of the HER-2/neu oncogene. Science. 1987;235:177–182
  6. Slamon D, Godolphin W, Jones L, et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science. 1989;244:707–712
  7. Ross JS, Fletcher JA. The HER-2/neu oncogene in breast cancer: Prognostic factor, predictive factor, and target for therapy. Stem Cells. 1998;16:413–428
  8. Revillion F, Bonneterre J, Peyrat JP. ERBB2 oncogene in human breast cancer and its clinical significance. Eur J Cancer. 1998;34:791–808
  9. Carlson RW, Brown E, Burstein HJ, et al. NCCN Task Force Report: Adjuvant Therapy for Breast Cancer. J Natl Compr Canc Netw. 2006;4(suppl 1):S1–S26
  10. Yaziji H, Goldstein LC, Barry TS, et al. HER-2 testing in breast cancer using parallel tissue-based methods. JAMA. 2004;291:1972–1977
  11. Benz CC, Scott GK, Sarup JC, et al. Estrogen-dependent, tamoxifen-resistant tumorigenic growth of MCF-7 cells transfected with HER2/neu. Breast Cancer Res Treat. 1992;24:85–95
  12. Pietras R, Arboleda J, Reese D, et al. HER-2 tyrosine kinase pathway targets estrogen receptor and promotes hormone-independent growth in human breast cancer cells. Oncogene. 1995;10:2435–2446
  13. Konecny G, Pauletti G, Pegram M, et al. Quantitative association between HER-2/neu and steroid hormone receptors in hormone receptor-positive primary breast cancer. J Natl Cancer Inst. 2003;95:142–153
  14. Shou J, Massarweh S, Osborne CK, et al. Mechanisms of tamoxifen resistance: Increased estrogen receptor-HER2/neu cross-talk in ER/HER2-positive breast cancer. J Natl Cancer Inst. 2004;96:926–935
  15. Liu Y, el-Ashry D, Chen D, et al. MCF-7 breast cancer cells overexpressing transfected c-erbB-2 have an in vitro growth advantage in estrogen-depleted conditions and reduced estrogen-dependence and tamoxifen-sensitivity in vivo. Breast Cancer Res Treat. 1995;34:97–117
  16. Kurokawa H, Lenferink AE, Simpson JF, et al. Inhibition of HER2/neu (erbB-2) and mitogen-activated protein kinases enhances tamoxifen action against HER2-overexpressing, tamoxifen-resistant breast cancer cells. Cancer Res. 2000;60:5887–5894
  17. McShane LM, Altman DG, Sauerbrei W, et al. Reporting recommendations for tumor marker prognostic studies. J Clin Oncol. 2005;23:9067–9072
  18. Fisher E, Sass R, Fisher B. Pathologic findings from the National Surgical Adjuvant Project for breast cancers (protocol no. 4). Cancer. 1984;53:712–723
  19. Yamauchi H, Stearns V, Hayes DF. When is a tumor marker ready for prime time? (A case study of c-erbB-2 as a predictive factor in breast cancer). J Clin Oncol. 2001;19:2334–2356
  20. Borg A, Baldetrop B, Ferno M, et al. ERBB2 amplification is associated with tamoxifen resistance in steroid-receptor positive breast cancer. Cancer Letters. 1994;81:137–144
  21. Sjogren S, Inganas M, Lindgren A, et al. Prognostic and predictive value of c-erbB-2 overexpression in primary breast cancer, alone and in combination with other prognostic markers. J Clin Oncol. 1998;16:462–469
  22. Carlomagno C, Perrone F, Gallo C, et al. c-erbB2 overexpression decreases the benefit of adjuvant tamoxifen in early-stage breast cancer without axillary lymph node metastases. J Clin Oncol. 1996;14:2702–2708
  23. De Placido S, De Laurentiis M, Carlomagno C, et al. Twenty-year results of the Naples GUN randomized trial: Predictive factors of adjuvant tamoxifen efficacy in early breast cancer. Clin Cancer Res. 2003;9:1039–1046
  24. Andrulis IL, Bull SB, Blackstein ME, et al. Toronto Breast Cancer Study Group neu/erbB-2 amplification identifies a poor-prognosis group of women with node-negative breast cancer. J Clin Oncol. 1998;16:1340–1349
  25. Knoop AS, Bentzen SM, Nielsen MM, et al. Value of epidermal growth factor receptor, HER2, p53, and steroid receptors in predicting the efficacy of tamoxifen in high-risk postmenopausal breast cancer patients. J Clin Oncol. 2001;19:3376–3384
  26. Berry DA, Muss HB, Thor AD, et al. HER-2/neu and p53 expression versus tamoxifen resistance in estrogen receptor-positive, node-positive breast cancer. J Clin Oncol. 2000;18:3471–3479
  27. Paik S, Bryant J, Park C, et al. erbB-2 and response to doxorubicin in patients with axillary lymph node-positive, hormone receptor-negative breast cancer. J Natl Cancer Inst. 1998;90:1361–1370
  28. Love RR, Duc NB, Allred DC, et al. Oophorectomy and tamoxifen adjuvant therapy in premenopausal Vietnamese and Chinese women with operable breast cancer. J Clin Oncol. 2002;20:2559–2566
  29. Love RR, Duc NB, Havighurst TC, et al. Her-2/neu overexpression and response to oophorectomy plus tamoxifen adjuvant therapy in estrogen receptor-positive premenopausal women with operable breast cancer. J Clin Oncol. 2003;21:453–457
  30. Stal O, Borg A, Ferno M, et al. ErbB2 status and the benefit from two or five years of adjuvant tamoxifen in postmenopausal early stage breast cancer. Ann Oncol. 2000;11:1545–1550
  31. Houston SJ, Plunkett TA, Barnes DM, et al. Overexpression of c-erbB2 is an independent marker of resistance to endocrine therapy in advanced breast cancer. Br J Cancer. 1999;79:1220–1226
  32. Berns EMJJ, Foekens JA, van Staveren IL, et al. Oncogene amplification and prognosis in breast cancer: Relationship with systemic treatment. Gene. 1995;159:11–18
  33. Wright C, Nicholson S, Angus B, et al. Relationship between c-erbB-2 protein product expression and response to endocrine therapy in advanced breast cancer. Br J Cancer. 1992;65:118–121
  34. Lipton A, Ali SM, Leitzel K, et al. Elevated serum Her-2/neu level predicts decreased response to hormone therapy in metastatic breast cancer. J Clin Oncol. 2002;20:1467–1472
  35. Leitzel K, Teramoto Y, Konrad K, et al. Elevated serum c-erbB-2 antigen levels and decreased response to hormone therapy of breast cancer. J Clin Oncol. 1995;13:1129–1135
  36. Yamauchi H, O’Neill A, Gelman R, et al. Prediction of response to antiestrogen therapy in advanced breast cancer patients by pretreatment circulating levels of extracellular domain of the HER-2/c-neu protein. J Clin Oncol. 1997;15:2518–2525
  37. Willsher PC, Beaver J, Pinder S, et al. Prognostic significance of serum c-erbB-2 protein in breast cancer patients. Breast Cancer Res Treat. 1996;40:251–255
  38. Elledge RM, Green S, Ciocca D, et al. HER-2 expression and response to tamoxifen in estrogen receptor–positive breast cancer: A Southwest Oncology Group Study. Clin Cancer Res. 1998;4:7–12
  39. De Laurentiis M, Arpino G, Massarelli E, et al. A meta-analysis on the interaction between HER-2 expression and response to endocrine treatment in advanced breast cancer. Clin Cancer Res. 2005;11:4741–4748
  40. Ellis MJ, Coop A, Singh B, et al. Letrozole is more effective neoadjuvant endocrine therapy than tamoxifen for ErbB-1- and/or ErbB-2-positive, estrogen receptor-positive primary breast cancer: Evidence from a phase III randomized trial. J Clin Oncol. 2001;19:3808–3816
  41. Smith IE, Dowsett M, Ebbs SR, et al. Neoadjuvant treatment of postmenopausal breast cancer with anastrozole, tamoxifen, or both in combination: the Immediate Preoperative Anastrozole, Tamoxifen, or Combined with Tamoxifen (IMPACT) multicenter double-blind randomized trial. J Clin Oncol. 2005;23:5108–5116
  42. Mouridsen H, Gershanovich M, Sun Y, et al. Superior efficacy of letrozole versus tamoxifen as first-line therapy for postmenopausal women with advanced breast cancer: Results of a phase III study of the International Letrozole Breast Cancer Group. J Clin Oncol. 2001;19:2596–2606
  43. Lipton A, Ali SM, Leitzel K, et al. Serum HER-2/neu and response to the aromatase inhibitor letrozole versus tamoxifen. J Clin Oncol. 2003;21:1967–1972
  44. Archer SG, Eliopoulos A, Spandidos D, et al. Expression of ras p21, p53 and c-erbB-2 in advanced breast cancer and response to first line hormonal therapy. Br J Cancer. 1995;72:1259–1266
  45. Fehm T, Maimonis P, Katalinic A, et al. The prognostic significance of c-erbB-2 serum protein in metastatic breast cancer. Oncology. 1998;55:33–38
  46. Hayes DF, Yamauchi H, Broadwater G, et al. Circulating HER-2/erbB-2/c-neu (HER-2) extracellular domain as a prognostic factor in patients with metastatic breast cancer: Cancer and Leukemia Group B Study 8662. Clin Cancer Res. 2001;7:2703–2711
  47. Jukkola A, Bloigu R, Soini Y, et al. c-erbB-2 positivity is a factor for poor prognosis in breast cancer and poor response to hormonal or chemotherapy treatment in advanced disease. Eur J Cancer. 2001;37:347–354

 T.M.P.’s work is supported by an American Society of Clinical Oncology Young Investigator Award and a Pearl M. Stetler Research Fund Award.

PII: S0093-7754(06)00327-7

doi: 10.1053/j.seminoncol.2006.08.016

Seminars in Oncology
Volume 33, Issue 6 , Pages 681-687 , December 2006

Article Tools